BR112022017425A2 - Usos terapêuticos de compostos macrocíclicos - Google Patents
Usos terapêuticos de compostos macrocíclicosInfo
- Publication number
- BR112022017425A2 BR112022017425A2 BR112022017425A BR112022017425A BR112022017425A2 BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2 BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A BR112022017425 A BR 112022017425A BR 112022017425 A2 BR112022017425 A2 BR 112022017425A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic uses
- macrocyclic compounds
- compounds
- mammals
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984159P | 2020-03-02 | 2020-03-02 | |
| PCT/US2021/020255 WO2021178296A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017425A2 true BR112022017425A2 (pt) | 2022-11-29 |
Family
ID=77613771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017425A BR112022017425A2 (pt) | 2020-03-02 | 2021-03-01 | Usos terapêuticos de compostos macrocíclicos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250262216A1 (https=) |
| EP (1) | EP4114530A4 (https=) |
| JP (1) | JP2023515687A (https=) |
| KR (1) | KR20230022151A (https=) |
| CN (1) | CN115397514A (https=) |
| AU (1) | AU2021229457A1 (https=) |
| BR (1) | BR112022017425A2 (https=) |
| CA (1) | CA3174455A1 (https=) |
| IL (1) | IL295938A (https=) |
| MX (1) | MX2022010945A (https=) |
| WO (1) | WO2021178296A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| US20240132517A1 (en) * | 2021-02-10 | 2024-04-25 | Goharmony Therapeutics (Shenzhen) Co., Ltd. | Macrocyclic compound, pharmaceutical composition, and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| RU2765181C2 (ru) * | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| US10689400B2 (en) * | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| CN111182903A (zh) * | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
-
2021
- 2021-03-01 EP EP21764224.8A patent/EP4114530A4/en not_active Withdrawn
- 2021-03-01 JP JP2022552626A patent/JP2023515687A/ja active Pending
- 2021-03-01 CN CN202180023879.XA patent/CN115397514A/zh active Pending
- 2021-03-01 CA CA3174455A patent/CA3174455A1/en active Pending
- 2021-03-01 BR BR112022017425A patent/BR112022017425A2/pt unknown
- 2021-03-01 WO PCT/US2021/020255 patent/WO2021178296A1/en not_active Ceased
- 2021-03-01 MX MX2022010945A patent/MX2022010945A/es unknown
- 2021-03-01 KR KR1020227034099A patent/KR20230022151A/ko active Pending
- 2021-03-01 IL IL295938A patent/IL295938A/en unknown
- 2021-03-01 AU AU2021229457A patent/AU2021229457A1/en not_active Abandoned
- 2021-03-01 US US17/905,503 patent/US20250262216A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250262216A1 (en) | 2025-08-21 |
| AU2021229457A1 (en) | 2022-10-20 |
| IL295938A (en) | 2022-10-01 |
| CN115397514A (zh) | 2022-11-25 |
| EP4114530A4 (en) | 2024-04-17 |
| MX2022010945A (es) | 2022-10-07 |
| CA3174455A1 (en) | 2021-09-10 |
| WO2021178296A1 (en) | 2021-09-10 |
| KR20230022151A (ko) | 2023-02-14 |
| JP2023515687A (ja) | 2023-04-13 |
| EP4114530A1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| MX383823B (es) | Macrociclos de diarilo quirales y usos de los mismo. | |
| MX386680B (es) | Polimorfo de macrociclo de diarilo. | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CL2011003346A1 (es) | Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente. | |
| UY28294A1 (es) | Dihidroquinazolinas sustituidas | |
| BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
| ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| GT200600240A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| BRPI0815708B8 (pt) | composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição | |
| BR112014031394A8 (pt) | Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
| EA200701113A1 (ru) | Макролиды | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| BR112022017425A2 (pt) | Usos terapêuticos de compostos macrocíclicos | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| CR20110226A (es) | Composición para tratar enfermedad | |
| DOP2024000254A (es) | Macrociclos de indazol y su uso | |
| BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis | |
| CL2022002239A1 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| BR112018014769A2 (pt) | ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos? | |
| BR112022023897A2 (pt) | Um composto de azelastina para uso como substância antiviral, uso de um composto de azelastina como desinfetante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |